Please wait

AbbVie Inc.

Guidance Including the Impact of Acquired IPR&D and Milestones Expense

(Unaudited)

 

(in millions, except per share data)			Quarter Ended September 30, 2025																		Full-Year Ended December 31, 2025
			Acquired IPR&D and Milestones Expense						Adjusted Diluted EPS Range												Acquired IPR&D and Milestones Expense						Adjusted Diluted EPS Range
									Low						High												Low						High
Previously announced guidance excluding Q3 2025 acquired IPR&D and milestones expense			$	—					$	3.24					$	3.28					$	1,071					$	11.88					$	12.08
Q3 2025 acquired IPR&D and milestones expense			2,680						(1.50)						(1.50)						2,680						(1.50)						(1.50)
Guidance including Q3 2025 acquired IPR&D and milestones expensea			$	2,680					$	1.74					$	1.78					$	3,751					$	10.38					$	10.58

a    The Company's 2025 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2025, as both cannot be reliably forecasted.

    1